RecruitingNot ApplicableNCT06325202

Closed Loop and Education for Hypoglycemia Awareness Restoration

Closed Loop and Education for Hypoglycemia Awareness Restoration (CLEAR), Conducted by the Impaired Awareness of Hypoglycemia Consortium (IAHC)


Sponsor

Milton S. Hershey Medical Center

Enrollment

324 participants

Start Date

Oct 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the CLEAR study is to determine the effect on counterregulatory responses (CRR) of intervening (by attempting to strictly avoid hypoglycemia) to improve awareness of hypoglycemic symptoms among adults with type 1 diabetes (T1D) who have impaired awareness of hypoglycemia (IAH). IAH affects 20-25% of adults with T1D, and rises with increasing duration of T1D.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria7

  • Clinical diagnosis of type 1 diabetes
  • Gold Score or Clarke Score ≥ 4 (highly associated with IAH)
  • Random non-fasting C-peptide \< 200 pmol/L
  • Diabetes duration ≥ 10 years
  • HbA1c \< 10.5%
  • Total Daily Insulin Dose of \< 1 unit/kg
  • Ability to read and speak English (because validated non-English versions of the cognitive tests and the educational interventions are not available)

Exclusion Criteria17

  • Medical conditions that limit participation in study activities, as determined by the PI (including but not limited to cognitive dysfunction, reduced hearing, reduced vision, cancer under active treatment, untreated angina, organ failure)
  • Active alcohol or drug abuse (as defined by DSM criteria of either 1) recurrent use of alcohol/drugs resulting in a failure to fulfill major role obligations at work, school, or home, 2) recurrent alcohol/drug use in situations in which it is physically hazardous, or 3) recurrent alcohol or drug-related legal problems)
  • Social determinants of health that limit participation in study activities, as determined by the PI (including but not limited to homelessness, food insecurity, inadequate social support)
  • Seizure disorder unrelated to hypoglycemia associated seizures, unless documented seizure-free for \>12 months and on a stable regimen of anti-convulsant therapy
  • Skin conditions that would preclude the use of a CGM
  • Super-physiologic exposure to steroids within one month of enrollment
  • eGFR \< 45 mL/min/1.73 m2
  • History of bariatric surgery that irreversibly alters gut innervation and structure
  • Hyper- or hypokalemia (serum potassium \>5.5 or \<3.5 mmol/L)\*
  • Hemoglobin \< 10 g/dL\*
  • Medical condition that requires intermittent or continuous use of glucocorticoids at greater than physiological replacement doses
  • Pregnancy, plan for pregnancy, or breast feeding
  • Abnormal thyroid function tests of clinical significance, as determined by PI\*
  • Liver transaminases \> 3 times the upper limit of normal\*
  • Hospitalization for mental illness in last year
  • History of adrenalectomy
  • At discretion of the PI, laboratory tests may be repeated once. If the participant is not eligible after the second attempt, then the participant. The participant may be screened again.

Interventions

DEVICEOmnipod 5 or Medtronic 780G

Omnipod 5 and Medtronic 780G are hybrid closed loop devices that provide automated insulin delivery.

BEHAVIORALMy HypoCOMPaSS Education

My HypoCOMPaSS is a brief, standardized psycho-educational program delivered in small groups. Facilitated discussions focus on advocating rigorous avoidance of hypoglycemia while maintaining time in target glycemic range.

BEHAVIORALHARPdoc Education

The HARPdoc program targets cognitions around hypoglycemia that act as barriers to hypoglycemia avoidance and recovery of awareness using motivational and cognitive approaches, delivered by diabetes educators, trained and supported by a clinical psychologist, in small group format.


Locations(8)

University of California, San Diego

La Jolla, California, United States

AdventHealth

Orlando, Florida, United States

University of Kentucky

Lexington, Kentucky, United States

University of Minnesota

Minneapolis, Minnesota, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Melbourne

Fitzroy, Victoria, Australia

University of Leicester

Leicester, United Kingdom

University of Sheffield

Sheffield, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06325202


Related Trials